Vision Loss Can Trigger Hallucinations, Yet Few Know Why
A common but little-known condition causes vivid hallucinations in people with severe vision loss, and experts say these visions are usually harmless.
For people with severe vision loss, seeing things that aren't there can be a startling experience. Yet according to experts, these hallucinations are a recognized and often benign consequence of eye disease. The phenomenon, sometimes called Charles Bonnet syndrome, occurs when the brain fills in missing visual information with vivid images—ranging from people and flowers to abstract patterns.
Despite its prevalence among those with significant sight impairment, awareness remains low. Many sufferers may fear they are developing dementia or a psychiatric condition, when in fact the visions are a direct result of the eyes' failing to send signals to the brain. The hallucinations are typically brief, non-threatening, and do not indicate a worsening of the underlying eye disease.
Experts emphasize that while the experience can be frightening, it is not harmful. They advise patients to discuss their symptoms with a doctor to rule out other causes, but reassure that in most cases no treatment is needed. Simply knowing the condition is common and benign can ease anxiety and help people cope with the visions when they occur.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.